🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Gemcitabine

    ACTUATE THERAPEUTICS, INC.

    Soft Tissue Sarcoma

    phase 2 small molecule terminated

    1 trial

  2. Gemcitabine 100 mg/ml Concentrate for Solution for Infusion, 9-ING-41, Abraxane 5 mg/ml powder for dispersion for infusion.

    ACTUATE THERAPEUTICS, INC.

    Refractory Hematologic Malignancies or Solid Tumors

    phase 2 small molecule active

    1 trial

  3. Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  4. Gemcitabine/Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  5. Genomically Directed Monotherapy

    Vera Therapeutics

    Malignant Neoplasm of Breast

    phase 2 small molecule completed

    1 trial

  6. Gentuximab

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  7. Givosiran

    Alnylam Netherlands B.V.

    Acute Intermittent Porphyria

    phase 2 small molecule completed

    1 trial

  8. Glasdegib

    Jazz Pharmaceuticals Ireland Limited

    Acute Myelogenous Leukemia (AML) Due to Therapy

    phase 2 small molecule active

    1 trial

  9. Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion.

    The George Institute

    previously untreated aggressive B-cell lymphoma

    phase 2 small molecule active

    1 trial

  10. Gluten- and casein-free diet

    United Therapeutics Europe Ltd

    Autism

    phase 2 other completed

    1 trial

  11. Glycosides Of Tripterygium Wilfordii Hook(GTW)

    The First People's Hospital of Lianyungang

    Henoch-Schönlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

  12. Glyoxalase 1 (Glo1) inducer

    United Therapeutics Europe Ltd

    Glucose Intolerance

    phase 2 other completed

    1 trial

  13. Golexanolone Placebo Capsules, oral capsules, soft, GR3027 10 mg

    COGNITION THERAPEUTICS INC

    Primary biliary cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  14. Grafalon 20 mg/ml koncentrát pro infuzní roztok

    The George Institute

    Type 1 diabetes

    phase 2 small molecule active

    1 trial

  15. Granexin® gel (200 μM)

    United Therapeutics Europe Ltd

    Second Degree Burn

    phase 2 small molecule terminated

    1 trial

  16. Green tea

    United Therapeutics Europe Ltd

    Lung Cancer Prevention

    phase 2 other completed

    1 trial

  17. Group A (FIT): Avapritinib + IA regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia With T(8;21)(Q22;Q22)

    phase 2 small molecule active

    1 trial

  18. Group A FMP2.1/AS01B

    United Therapeutics Europe Ltd

    Malaria

    phase 2 mab completed

    1 trial

  19. Group A：Patients with PR or ctDNA positivity after salvage treatment

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma(DLBCL)

    phase 2 small molecule active

    1 trial

  20. Guttmann NeuroRecovery – Feasibility, safety and efficacy of intrathecal Wharton's jelly-derived mesenchymal stem cells and transcutaneous spinal cord stimulation in the rehabilitation of chronic spinal cord injuries: a pilot study

    The George Institute

    Traumatic spinal cord injury

    phase 2 other active

    1 trial

  21. HB-adMSC

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 mab terminated

    1 trial

  22. HB0043

    The First People's Hospital of Lianyungang

    Acne Vulgaris

    phase 2 small molecule active

    1 trial

  23. HMB-001

    Hemab Therapeutics Holdings

    Glanzmann Thrombasthenia

    phase 2 small molecule active

    1 trial

  24. HMB-001

    Hemab Therapeutics Holdings

    Glanzmann Thrombasthenia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources